Yinghui Medicine Secures Tens of Millions in Series A1 Financing to Advance Oncolytic Virus Candidate YH01 into Phase I Clinical Trials

Recently,Suzhou Yinghui Medical Technology Co., Ltd. (hereinafter referred to as "Yinghui Pharma") has successfully completed its Series A1 financing, raising tens of millions of RMB. This equity financing round was exclusively invested by Shengyuan Zhiben. The funds will be used to support the Phase I clinical trials of Yinghui Pharma's oncolytic virus product, YH01.。

Suzhou Yinghui is an innovative oncolytic virus enterprise in China with full-chain industrial capabilities encompassing the design, construction, validation, process development, and large-scale manufacturing of oncolytic viruses. Its key technologies are at the international leading level. The project team is led by Huang Yinghui, a renowned international expert in virology, Tenured Professor at the Torrey Pines Institute in California, USA, and former Dean of the College of Life Sciences and Bioengineering at Beijing University of Technology. The team includes fellows of the Royal Society of the United Kingdom and top-tier experts from Beijing, as well as operational specialists with extensive corporate management experience and industry experts with rich commercialization experience. The company has secured a substantial portfolio of core technologies with independent intellectual property rights. Suzhou Yinghui currently has five products in its pipeline. The most advanced candidate, YH01, targets triple-negative breast cancer (TNBC). In vivo and in vitro studies have demonstrated that this product delivers disruptive therapeutic efficacy, and it is currently in Phase I clinical trials.

Professor Huang Yinghui has dedicated over two decades abroad to the research of oncolytic viruses, establishing the OCDP™ (Oncolytic Core Design Platform) technology platform. This platform boasts robust multi-pipeline product design capabilities and internationally leading process development expertise, resulting in the successful development of more than ten oncolytic virus candidates. The product R&D design and manufacturing process technologies pioneered by the Yinghui Medical team are first-of-their-kind in China. The company holds an internationally leading position in oncolytic virus R&D technology platforms, comprehensively addressing key industry pain points and delivering products with outstanding therapeutic efficacy.

Professor Huang Yinghui, Founder of Suzhou YinghuiStatement: We sincerely appreciate the recognition and support from Zhejiang Shengyuan Zhiben Asset Management Co., Ltd. Viruses are powerful weapons; the key lies in how to tame them. Oncolytic virus therapy is a promising strategy for potentially curing cancer, yet its advantages and potential have not been fully realized to date. With over two decades of foundational research and technical accumulation in this field, we possess extensive experience and proficient expertise in the genetic engineering of viruses, along with a profound understanding of tumor pathogenesis and gene-based anticancer strategies. Our product is a true First-in-Class original innovative drug, designed completely independently of any existing domestic or international products. Coincidentally, it incorporates features characteristic of two recently disclosed international star anticancer products, Adstiladrin and CG0070. Currently, it demonstrates remarkable anticancer efficacy against various solid tumors, specifically killing cancer cells while sparing normal cells.

Dr. Guo Yongzhi, Partner at Shengyuan ZhibenStatement: Against the backdrop of the current capital winter, coupled with significant pain points in the oncolytic virus sector and intense homogeneous competition, many investment institutions have expressed skepticism regarding domestic oncolytic virus projects. Yinghui Medical’s oncolytic virus therapy is a genuine orthodoxy that emphasizes the direct oncolytic effect of the virus rather than merely using it as a vector. Its safety, efficacy, technological leadership, and level of industrialization far surpass those of comparable products. CG Oncology, which pursues a similar technical direction to Yinghui Medical, has reported a complete response rate of up to 75.7% in the treatment of bladder cancer, further bolstering our confidence. Currently disclosed clinical-stage data indicate that YH01 has already demonstrated remarkable efficacy at low doses. We anticipate that Yinghui Medical’s product will deliver disruptive therapeutic outcomes in clinical practice, enabling oncolytic virus technology to save a vast number of cancer patients.

Zhejiang Shengyuan Zhiben Asset Management Co., Ltd. was established in 2014, with its headquarters located in the Yuhuangshan South Fund Town in Shangcheng District, Hangzhou. The company specializes in industrial financial services and operates professional service platforms including an asset management company and an equity investment fund management company. Its business scope covers various fields such as debt financing, equity investment, and supply chain finance.

The company is committed to cultivating a cohort of leading enterprises in technological innovation and industrial upgrading by leveraging its financial expertise. Adhering to the core values of “maintaining vigilance in times of prosperity, mastering fundamentals while perceiving subtleties, pursuing excellence with utmost wisdom, and prioritizing substance and pragmatism,” it integrates industry with capital and entrepreneurs with financiers. This approach delivers safe, stable, and sustainable returns to investment partners while providing comprehensive financial empowerment solutions for the real economy.